At ACM Biolabs we are focused on developing novel vaccines using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using multiple antigens and have a growing pipeline of vaccines.
The company is headquartered in Singapore, and has been operational since 2013.
Dr. Madhavan Nallani
Founder & CEO
Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering and also at Nanyang Technological University).
Dr. Peter Moran
Previously co-founded Singular ID, a successful Singapore technology company which was acquired by one of the world’s largest pharmaceutical packaging companies.
Dr. Erich Erber
Founder the Erber Group, an Austrian animal nutrition company, which consists of more than 50 affiliates in all continents. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.
Erich is the key investor representative on ACM Biolabs' Board of Directors.
ACM Biolabs is backed by government bodies, investment companies and strategic corporate investors such as: San Pacific an investment group associated with the Erber Group, an Austrian Animal Healthcare multinational; Nagase, a Japanese multinational with diverse business interests, and; NTUitive, the innovation and enterprise company of the Nanyang Technological University.